Exane Derivatives’s Krystal Biotech KRYS Stock Holding History

Exane Derivatives’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-2,016	Closed	-$87.2K	–	724
2020 Q1	$87.2K	Buy	+2,016	New	+$105K	0.02%	297

Other funds holding KRYS

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Exane Derivatives's KRYS Position: Q2 2020 in Review

Exane Derivatives sold out of Krystal Biotech (KRYS) in Q2 2020, closing a stake of 2,016 shares — an estimated $87.2K sold.

Exane Derivatives first reported a position in KRYS in Q1 2020 and held it in 1 quarter. The position peaked at $87.2K in Q1 2020. 110 funds tracked by Wall St. Rank hold KRYS as of Q2 2020.

Exane Derivatives reported no remaining Krystal Biotech position as of Q2 2020 after selling out during the quarter.
Exane Derivatives sold 2,016 Krystal Biotech shares in Q2 2020, an estimated $87.2K.
Exane Derivatives first reported a position in Krystal Biotech in Q1 2020 and held it in 1 quarter.
Exane Derivatives's Krystal Biotech position peaked at $87.2K in Q1 2020.
110 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2020.

Based on Exane Derivatives's 13F filing for Q2 2020, filed 10 Jul 2020.